FDA turmoil, revived gene therapy, weak Alzheimer’s
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- STAT+ article reports FDA turmoil over Commissioner Marty Makary’s potential ouster.
- STAT+ article highlights a resurrected gene‑therapy effort for a once‑devastated rare disease program.
- STAT+ article notes underwhelming adoption of an Alzheimer’s drug.
- STAT+ article is exclusive to STAT+ subscribers.
Why it matters: Patients with the rare disease gain renewed therapeutic hope, while the FDA’s leadership shake‑up undermines regulatory stability and Alzheimer’s drug makers face lower sales, reshaping biotech investment priorities.
Ask SkimNews
